Artelo Biosciences effects 1-for-3 reverse stock split effective March 10, 2026

ARTELO BIOSCIENCES, INC.

Reverse split ratio 1-for-3; outstanding shares reduced from 2,124,772 to ~708,258.
Effective at market open on March 10, 2026; new CUSIP 04301G706.
No fractional shares issued; holders otherwise entitled to fractional share receive one whole share.
All outstanding warrants and other derivatives adjust automatically per their terms.
Board approved without stockholder vote under Nevada Revised Statutes 78.207.

item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

ARTELO BIOSCIENCES, INC. issued common stock.

Security: common stock

Exact text from the filing

on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split ("Reverse Split") of the Company’s common stock ("Common Stock").

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ARTELO BIOSCIENCES, INC.: Effected a one-for-three reverse stock split of common stock and reduced authorized shares accordingly (effective 2026-03-10).

Change: charter amendment
Effective: 2026-03-10

Exact text from the filing

On March 5, 2026, Artelo Biosciences, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-three (1-for-3) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).

View on SEC.gov

Browse all equity issuances →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.